FGFR2 and cancer: The presence of FGFR2 alterations predicts poor response to standard TKIs such as imatinib, necessitating alternative therapies. FGFR inhibitors, such as erdafitinib and pemigatinib, approved for other FGFR-driven cancers, show preclinical promise in FGFR2-altered GISTs.